[go: up one dir, main page]

AU2001240820A1 - Proteins, genes and their use for diagnosis and treatment of vascular dementia - Google Patents

Proteins, genes and their use for diagnosis and treatment of vascular dementia

Info

Publication number
AU2001240820A1
AU2001240820A1 AU2001240820A AU4082001A AU2001240820A1 AU 2001240820 A1 AU2001240820 A1 AU 2001240820A1 AU 2001240820 A AU2001240820 A AU 2001240820A AU 4082001 A AU4082001 A AU 4082001A AU 2001240820 A1 AU2001240820 A1 AU 2001240820A1
Authority
AU
Australia
Prior art keywords
genes
diagnosis
proteins
treatment
vascular dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001240820A
Inventor
Herath Mudiyanselage Athula Chandrasiri Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0006285A external-priority patent/GB0006285D0/en
Priority claimed from GB0028734A external-priority patent/GB0028734D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2001240820A1 publication Critical patent/AU2001240820A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00Electrophoretic profiling, e.g. for proteome analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
AU2001240820A 2000-03-15 2001-03-14 Proteins, genes and their use for diagnosis and treatment of vascular dementia Abandoned AU2001240820A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0006285A GB0006285D0 (en) 2000-03-15 2000-03-15 Proteins and their use for diagnosis and treatment of vascular dementia
GB0006285 2000-03-15
GB0028734 2000-11-24
GB0028734A GB0028734D0 (en) 2000-11-24 2000-11-24 Markers for vascular dementia
US72439100A 2000-11-28 2000-11-28
US09724391 2000-11-28
PCT/GB2001/001106 WO2001069261A2 (en) 2000-03-15 2001-03-14 Proteins, genes and their use for diagnosis and treatment of vascular dementia

Publications (1)

Publication Number Publication Date
AU2001240820A1 true AU2001240820A1 (en) 2001-09-24

Family

ID=27255598

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001240820A Abandoned AU2001240820A1 (en) 2000-03-15 2001-03-14 Proteins, genes and their use for diagnosis and treatment of vascular dementia

Country Status (3)

Country Link
EP (1) EP1264183A2 (en)
AU (1) AU2001240820A1 (en)
WO (1) WO2001069261A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002222308A1 (en) * 2000-12-29 2002-07-16 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular response
US20030100012A1 (en) * 2001-11-23 2003-05-29 George Jackowski Plasma protease C1 biopolymer markers predictive of alzheimers disease
US7052849B2 (en) * 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
US11543418B2 (en) 2017-07-13 2023-01-03 Kazuhiko Uchida Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using biomarker
CN111773204B (en) * 2019-04-03 2023-01-24 上海市浦东新区浦南医院 Application of sodium dichloroacetate in preparing medicine for treating vascular dementia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7128494A (en) * 1993-07-09 1995-02-06 Celltech Limited Gelatinase antagonists used for treating cancer
US5677277A (en) * 1994-05-09 1997-10-14 Research Development Foundation Brain endothelial cell protein induced by nerve growth factor
WO1995035373A2 (en) * 1994-06-10 1995-12-28 La Jolla Cancer Research Foundation Nucleic acid molecules encoding human contactin
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US5766922A (en) * 1995-05-26 1998-06-16 Sugen, Inc. Functional ligands for the axonal cell rcognition molecule contactin
JP3646191B2 (en) * 1996-03-19 2005-05-11 大塚製薬株式会社 Human gene
EP1208228A2 (en) * 1999-05-19 2002-05-29 Mitokor Differential gene expression in specific regions of the brain in neurodegenerative diseases
WO2001026671A1 (en) * 1999-10-12 2001-04-19 Smithkline Beecham Corporation Methods of treatment using dual matrix-metalloproteinase-2 and matrix metalloproteinase-9 inhibitors

Also Published As

Publication number Publication date
EP1264183A2 (en) 2002-12-11
WO2001069261A3 (en) 2002-05-16
WO2001069261A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
AU2002216273A1 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
AU2002341876A1 (en) Methods and devices for treating diseased blood vessels
AU2002323258A1 (en) Diagnosis and treatment of vascular disease
AU3083301A (en) Improved tissue engineered blood vessels and methods and apparatus for their manufacture
AU5788300A (en) Medical treatment method and kit
AU2002241520A1 (en) Blood assessment of injury
AU2002367535A1 (en) Diagnosis and treatment of vascular disease
AU2002219229A1 (en) Means for the diagnosis and therapy of CTCL
AU6118600A (en) Magnetic toroids for the stimulation of biological tissue
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU7748200A (en) Hypoxia-related human genes, proteins, and uses thereof
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2002240336A1 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
AU2002339439A1 (en) Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2002220266A1 (en) Methods for the identification and the treatment of cardiovascular disease
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
AU3760400A (en) Methods and reagents for the diagnosis and treatment of multiple sclerosis
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
AU2067501A (en) Human oxidoreductase proteins
AU2001240820A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
AU2001233954A1 (en) Proteins, genes and their use for diagnosis and treatment of schizophrenia
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states